OpGen, Inc.

08/14/2023

What is the Global Antibiotic Research & Development Partnership doing to combat , which was last year identified as one of the world’s leading causes of death. Learn more here: https://gardp.org/annual-report-2022/

08/11/2023

The Candida auris multi-drug-resistant and pan-resistant fungus poses a global health threat for three main reasons. It is often resistant to anti-fungal drugs, is difficult to identify and can spread in hospitals and nursing homes. Find out more in Episode 10 of the Superbugs and You podcast: https://ow.ly/IRwI50PoSNZ

Infections caused by highly drug resistant bacteria or ​“superbugs” are becoming more and more common, making antimicrobial resistance one of the world’s greatest health threats.

08/09/2023

The World Health Organization has published the first global research agenda to address urgent health priorities to counter : https://ow.ly/alGW50PoSui

Policy brief

08/08/2023

The development of antimicrobials to address has been hindered by a flawed marketplace which has resulted in a steady decline in the number of phase-III antibiotic candidates over the past 9 years.
The number of first-time drug approvals from 2020 to 2022 was ‘disappointingly low’ but there is still hope. Read this new study:

The need for new antibacterial drugs to treat the increasing global prevalence of drug-resistant bacterial infections has clearly attracted global attention, with a range of existing and upcoming funding, policy, and legislative initiatives designed to revive antibacterial R&D. It is essential t...

08/07/2023

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Read our latest update here: https://ir.opgen.com/news-releases/news-release-details/opgens-subsidiary-ares-genetics-releases-new-features-its

08/04/2023

A new study has been launched to find out more about how is best tackled in healthy people.
Up to 2,000 people across different UK populations are to be invited to submit stool samples and nose and throat swabs for the study, which will help scientists understand more about the factors influencing bacteria in our body.
By understanding more about the drivers of in the community, scientists hope to be better able to design ways to reduce antimicrobial-resistant infections.
Read here for more details:

The study aims to learn about antimicrobial resistance in healthy people to inform better ways of tackling antimicrobial resistant infections in different populations.

08/03/2023

Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICs Next phase to cover full AMR assay and cartridge development, analytical testing and software development Related payments of up to approximately $0.6

08/03/2023

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

Read the full release here:

Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICs Next phase to cover full AMR assay and cartridge development, analytical testing and software development Related payments of up to approximately $0.6

08/03/2023

Join us to hear about ‘Multiplex Molecular Panel as a Supplement to Routine Culture for Tissue Infection’ poster by C. R. Cox et al at the 33rd Annual Open Scientific Meeting of the Musculoskeletal Infection Society in Salt Lake City, Utah from August 4-5 (Monitor 5, 23-AEP-1087):

PROGRAM General information 33rd Annual Open Scientific Meeting Musculoskeletal Infection Society Aug 4-5, 2023 Salt Lake City, Utah United States In Person and Virtual meeting with podium, poster and symposia presentations Registration Starts from: 28-Feb-2023 to 30-Jul-2023 LOGIN TO MEETING Meetin...

08/02/2023

A new network is being set up to help tackle the main drivers of . The Centres for Antimicrobial Optimisation Network (CAMO-Net), funded by Wellcome, will be based at Imperial College London and University of Liverpool.
The aim is to address the global impact of AMR on human health by fostering research partnerships across low, middle and high resource settings and across urban and rural environments.
More details here:

The new network called CAMO-Net will support translational research to help tackle the main drivers of antimicrobial resistance.

07/31/2023

Global estimates of hospital-acquired -resistant infections now top 136 million a year. China, Pakistan and India are new hot-spots but, among high income countries, the USA is faring worst. More details in this new blockbuster report: https://ow.ly/oBSJ50P1ys0

Ruchita Balasubramanian and colleagues, estimate the incidence of hospital-associated infections resistant to antibiotics in 195 countries using point prevalence survey data from across the globe.

07/28/2023

Effectively combatting requires a paradigm shift from the pharmaceuticals industry - but right now the kind of small biotech firms responsible for developing most new antibiotics continue to face bankruptcy. That was the frightening conclusion of a recent webinar. Watch it here🎥:

Congressional policymakers, federal policymakers, their advisors, and stakeholders interested in addressing drug-resistant infections and antimicrobial resis...